{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T02:11:50Z","timestamp":1781835110130,"version":"3.54.5"},"reference-count":100,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,26]],"date-time":"2024-10-26T00:00:00Z","timestamp":1729900800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,10,26]],"date-time":"2024-10-26T00:00:00Z","timestamp":1729900800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002332","name":"Semmelweis University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002332","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Recent advances in genomics and proteomics have helped in understanding the molecular mechanisms and pathways of comorbidities and heart failure. In this narrative review, we reviewed molecular alterations in common comorbidities associated with heart failure such as obesity, diabetes mellitus, systemic hypertension, pulmonary hypertension, coronary artery disease, hypercholesteremia and lipoprotein abnormalities, chronic kidney disease, and atrial fibrillation. We searched the electronic databases, PubMed, Ovid, EMBASE, Google Scholar, CINAHL, and PhysioNet for articles without time restriction. Although the association between comorbidities and heart failure is already well established, recent studies have explored the molecular pathways in much detail. These molecular pathways demonstrate how novels drugs for heart failure works with respect to the pathways associated with comorbidities. Understanding the altered molecular milieu in heart failure and associated comorbidities could help to develop newer medications and targeted therapies that incorporate these molecular alterations as well as key molecular variations across individuals to improve therapeutic outcomes. The molecular alterations described in this study could be targeted for novel and personalized therapeutic approaches in the future. This knowledge is also critical for developing precision medicine strategies to improve the outcomes for patients living with these conditions.<\/jats:p>","DOI":"10.1007\/s11033-024-10024-7","type":"journal-article","created":{"date-parts":[[2024,10,26]],"date-time":"2024-10-26T14:02:02Z","timestamp":1729951322000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Molecular remodeling in comorbidities associated with heart failure: a current update"],"prefix":"10.1007","volume":"51","author":[{"given":"Sandeep","family":"Appunni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muni","family":"Rubens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venkataraghavan","family":"Ramamoorthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anshul","family":"Saxena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"McGranaghan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atulya","family":"Khosla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayur","family":"Doke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Chaparro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Jimenez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,26]]},"reference":[{"issue":"4","key":"10024_CR1","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.cardfail.2021.01.022","volume":"27","author":"B Bozkurt","year":"2021","unstructured":"Bozkurt B, Coats AJ, Tsutsui H, Abdelhamid M, Adamopoulos S, Albert N et al (2021) Universal definition and classification of heart failure: a report of the heart failure society of America, heart failure association of the European society of cardiology, Japanese heart failure society and writing committee of the universal definition of heart failure. J Card Fail 27(4):387\u2013413","journal-title":"J Card Fail"},{"issue":"5","key":"10024_CR2","doi-asserted-by":"crossref","first-page":"bbab061","DOI":"10.1093\/bib\/bbab061","volume":"22","author":"S Doran","year":"2021","unstructured":"Doran S, Arif M, Lam S, Bayraktar A, Turkez H, Uhlen M et al (2021) Multi-omics approaches for revealing the complexity of cardiovascular disease. Brief Bioinform 22(5):bbab061","journal-title":"Brief Bioinform"},{"key":"10024_CR3","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1007\/s00204-015-1477-x","volume":"89","author":"YK Tham","year":"2015","unstructured":"Tham YK, Bernardo BC, Ooi JY, Weeks KL, McMullen JR (2015) Pathophysiology of cardiac hypertrophy and heart failure: signaling pathways and novel therapeutic targets. Arch Toxicol 89:1401\u20131438","journal-title":"Arch Toxicol"},{"key":"10024_CR4","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.pharmthera.2016.03.005","volume":"161","author":"Y Zhang","year":"2016","unstructured":"Zhang Y, Ren J (2016) Epigenetics and obesity cardiomyopathy: from pathophysiology to prevention and management. Pharmacol Ther 161:52\u201366","journal-title":"Pharmacol Ther"},{"issue":"5","key":"10024_CR5","doi-asserted-by":"crossref","first-page":"4321","DOI":"10.3390\/ijms24054321","volume":"24","author":"V Tsigkou","year":"2023","unstructured":"Tsigkou V, Oikonomou E, Anastasiou A, Lampsas S, Zakynthinos GE, Kalogeras K et al (2023) Molecular mechanisms and therapeutic implications of endothelial dysfunction in patients with heart failure. Int J Mol Sci 24(5):4321","journal-title":"Int J Mol Sci"},{"key":"10024_CR6","doi-asserted-by":"crossref","unstructured":"Screever EM, van der Wal MH, van Veldhuisen DJ, Jaarsma T, Koops A, van Dijk KS et al (2023) Comorbidities complicating heart failure: changes over the last 15 years. Clin Res Cardiol 112(1):123\u2013133","DOI":"10.1007\/s00392-022-02076-1"},{"issue":"4","key":"10024_CR7","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1002\/ejhf.1433","volume":"21","author":"P Kokkinos","year":"2019","unstructured":"Kokkinos P, Faselis C, Franklin B, Lavie CJ, Sidossis L, Moore H et al (2019) Cardiorespiratory fitness, body mass index and heart failure incidence. Eur J Heart Fail 21(4):436\u2013444","journal-title":"Eur J Heart Fail"},{"key":"10024_CR8","doi-asserted-by":"crossref","unstructured":"Benn M, Marott SC, Tybj\u00e6rg-Hansen A, Nordestgaard BG (2023) Obesity increases heart failure incidence and mortality: observational and mendelian randomization studies totalling over 1 million individuals. Cardiovascular Res 118(18):3576\u20133585","DOI":"10.1093\/cvr\/cvab368"},{"issue":"3","key":"10024_CR9","doi-asserted-by":"crossref","first-page":"160","DOI":"10.36628\/ijhf.2020.0047","volume":"3","author":"Q Shen","year":"2021","unstructured":"Shen Q, Hiebert JB, Rahman FK, Krueger KJ, Gupta B, Pierce JD (2021) Understanding obesity-related high output heart failure and its implications. Int J Heart Fail 3(3):160\u2013171","journal-title":"Int J Heart Fail"},{"issue":"10","key":"10024_CR10","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1161\/CIRCRESAHA.121.318241","volume":"128","author":"GD Lopaschuk","year":"2021","unstructured":"Lopaschuk GD, Karwi QG, Tian R, Wende AR, Abel ED (2021) Cardiac energy metabolism in heart failure. Circul Res 128(10):1487\u20131513","journal-title":"Circul Res"},{"issue":"8","key":"10024_CR11","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1161\/CIRCULATIONAHA.121.053889","volume":"144","author":"T Satoh","year":"2021","unstructured":"Satoh T, Wang L, Espinosa-Diez C, Wang B, Hahn SA, Noda K et al (2021) Metabolic syndrome mediates ROS-miR-193b-NFYA\u2013Dependent downregulation of Soluble Guanylate Cyclase and contributes to Exercise-Induced Pulmonary Hypertension in Heart failure with preserved ejection fraction. Circulation 144(8):615\u2013637","journal-title":"Circulation"},{"issue":"1","key":"10024_CR12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-021-21931-9","volume":"12","author":"GG Schiattarella","year":"2021","unstructured":"Schiattarella GG, Altamirano F, Kim SY, Tong D, Ferdous A, Piristine H et al (2021) Xbp1s-FoxO1 axis governs lipid accumulation and contractile performance in heart failure with preserved ejection fraction. Nat Commun 12(1):1\u201314","journal-title":"Nat Commun"},{"key":"10024_CR13","doi-asserted-by":"crossref","first-page":"107424842311622","DOI":"10.1177\/10742484231162249","volume":"28","author":"X Wang","year":"2023","unstructured":"Wang X, Xu Z, Chang R, Zeng C, Zhao Y (2023) High-fructose Diet induces Cardiac Dysfunction via Macrophage Recruitment in Adult mice. J Cardiovasc Pharmacol Therap 28:10742484231162249","journal-title":"J Cardiovasc Pharmacol Therap"},{"issue":"16","key":"10024_CR14","doi-asserted-by":"crossref","first-page":"4416","DOI":"10.1111\/jcmm.17466","volume":"26","author":"C Almengl\u00f3","year":"2022","unstructured":"Almengl\u00f3 C, Fu X, Flores-Arias MT, Fern\u00e1ndez \u00c1L, Vi\u00f1uela JE, Mart\u00ednez\u2010Cereijo JM et al (2022) Synergism between obesity and HFpEF on neutrophils phenotype and its regulation by adipose tissue\u2010molecules and SGLT2i dapagliflozin. J Cell Mol Med 26(16):4416\u20134427","journal-title":"J Cell Mol Med"},{"issue":"10","key":"10024_CR15","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1038\/s41401-022-00885-8","volume":"43","author":"K Lin","year":"2022","unstructured":"Lin K, Yang N, Luo W, Qian J-f, Zhu W-w, Ye S-j et al (2022) Direct cardio-protection of Dapagliflozin against obesity-related cardiomyopathy via NHE1\/MAPK signaling. Acta Pharmacol Sin 43(10):2624\u20132635","journal-title":"Acta Pharmacol Sin"},{"key":"10024_CR16","doi-asserted-by":"crossref","unstructured":"Jha KK, Adhikari R, Tasdighi E, Osuji N, Rajan T, Blaha MJ (2022) Transitioning to GLP-1 RAs and SGLT2 inhibitors as the first choice for managing cardiometabolic risk in type 2 diabetes. Curr Atheroscler Rep 24(12):925\u2013937","DOI":"10.1007\/s11883-022-01066-y"},{"issue":"41","key":"10024_CR17","doi-asserted-by":"crossref","first-page":"4406","DOI":"10.1093\/eurheartj\/ehac481","volume":"43","author":"C Adamson","year":"2022","unstructured":"Adamson C, Kondo T, Jhund PS, de Boer RA, Cabrera Honorio JW, Claggett B et al (2022) Dapagliflozin for heart failure according to body mass index: the DELIVER trial. Eur Heart J 43(41):4406\u20134417","journal-title":"Eur Heart J"},{"issue":"31","key":"10024_CR18","doi-asserted-by":"crossref","first-page":"2958","DOI":"10.1093\/eurheartj\/ehab530","volume":"43","author":"K Oyama","year":"2022","unstructured":"Oyama K, Raz I, Cahn A, Kuder J, Murphy SA, Bhatt DL et al (2022) Obesity and effects of dapagliflozin on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus in the DECLARE\u2013TIMI 58 trial. Eur Heart J 43(31):2958\u20132967","journal-title":"Eur Heart J"},{"key":"10024_CR19","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.crphys.2022.05.003","volume":"5","author":"B Xie","year":"2022","unstructured":"Xie B, Ramirez W, Mills AM, Huckestein BR, Anderson M, Pangburn MM et al (2022) Empagliflozin restores cardiac metabolic flexibility in diet-induced obese C57BL6\/J mice. Curr Res Physiol 5:232\u2013239","journal-title":"Curr Res Physiol"},{"key":"10024_CR20","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.lfs.2019.05.051","volume":"230","author":"T Takasu","year":"2019","unstructured":"Takasu T, Takakura S (2019) Effect of ipragliflozin, an SGLT2 inhibitor, on cardiac histopathological changes in a non-diabetic rat model of cardiomyopathy. Life Sci 230:19\u201327","journal-title":"Life Sci"},{"issue":"7","key":"10024_CR21","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.2337\/dc20-2518","volume":"44","author":"IR Mordi","year":"2021","unstructured":"Mordi IR, Lumbers RT, Palmer CN, Pearson ER, Sattar N, Holmes MV et al (2021) Type 2 diabetes, metabolic traits, and risk of Heart failure: a mendelian randomization study. Diabetes Care 44(7):1699\u20131705","journal-title":"Diabetes Care"},{"issue":"12","key":"10024_CR22","doi-asserted-by":"crossref","first-page":"4098","DOI":"10.3390\/ijms19124098","volume":"19","author":"A Maffei","year":"2018","unstructured":"Maffei A, Lembo G, Carnevale D (2018) PI3Kinases in diabetes mellitus and its related complications. Int J Mol Sci 19(12):4098","journal-title":"Int J Mol Sci"},{"key":"10024_CR23","doi-asserted-by":"crossref","unstructured":"Han Z, Zhao D, Han M, Zhang R, Hao Y (2022) Knockdown of miR-372-3p Inhibits the Development of Diabetic Cardiomyopathy by Accelerating Angiogenesis via Activating the PI3K\/AKT\/mTOR\/HIF-1\u03b1 Signaling Pathway and Suppressing Oxidative Stress. Oxidative Medicine and Cellular Longevity. 2022","DOI":"10.1155\/2022\/4342755"},{"issue":"11","key":"10024_CR24","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1161\/CIRCRESAHA.121.318988","volume":"131","author":"X Wu","year":"2022","unstructured":"Wu X, Liu H, Brooks A, Xu S, Luo J, Steiner R et al (2022) SIRT6 mitigates heart failure with preserved ejection fraction in diabetes. Circul Res 131(11):926\u2013943","journal-title":"Circul Res"},{"issue":"9","key":"10024_CR25","doi-asserted-by":"crossref","first-page":"109190","DOI":"10.1016\/j.celrep.2021.109190","volume":"35","author":"D Khan","year":"2021","unstructured":"Khan D, Ara T, Ravi V, Rajagopal R, Tandon H, Parvathy J et al (2021) SIRT6 transcriptionally regulates fatty acid transport by suppressing PPAR\u03b3. Cell Rep 35(9):109190","journal-title":"Cell Rep"},{"issue":"12","key":"10024_CR26","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1161\/CIRCRESAHA.119.314898","volume":"125","author":"H Li","year":"2019","unstructured":"Li H, Fan J, Zhao Y, Zhang X, Dai B, Zhan J et al (2019) Nuclear miR-320 mediates diabetes-induced cardiac dysfunction by activating transcription of fatty acid metabolic genes to cause lipotoxicity in the heart. Circul Res 125(12):1106\u20131120","journal-title":"Circul Res"},{"issue":"1","key":"10024_CR27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12933-022-01458-z","volume":"21","author":"S Veitch","year":"2022","unstructured":"Veitch S, Njock M-S, Chandy M, Siraj MA, Chi L, Mak H et al (2022) MiR-30 promotes fatty acid beta-oxidation and endothelial cell dysfunction and is a circulating biomarker of coronary microvascular dysfunction in pre-clinical models of diabetes. Cardiovasc Diabetol 21(1):1\u201318","journal-title":"Cardiovasc Diabetol"},{"key":"10024_CR28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.yjmcc.2020.09.003","volume":"149","author":"J Mu","year":"2020","unstructured":"Mu J, Zhang D, Tian Y, Xie Z, Zou M-h (2020) BRD4 inhibition by JQ1 prevents high-fat diet-induced diabetic cardiomyopathy by activating PINK1\/Parkin-mediated mitophagy in vivo. J Mol Cell Cardiol 149:1\u201314","journal-title":"J Mol Cell Cardiol"},{"key":"10024_CR29","doi-asserted-by":"crossref","first-page":"6549","DOI":"10.2147\/IJGM.S325339","volume":"14","author":"Z Wang","year":"2021","unstructured":"Wang Z, Gu Y, Sun Y, Xu Y, Zhang M, Jiang T (2021) Analysis of communal molecular mechanism and potential therapeutic targets in heart failure and type 2 diabetes Mellitus. Int J Gen Med 14:6549","journal-title":"Int J Gen Med"},{"key":"10024_CR30","doi-asserted-by":"crossref","unstructured":"Guo Q, Zhu Q, Zhang T, Qu Q, Cheang I, Liao S et al (2022) Integrated bioinformatic analysis reveals immune molecular markers and potential drugs for diabetic cardiomyopathy. Front Endocrinol (Lausanne) 15(13):933635","DOI":"10.3389\/fendo.2022.933635"},{"key":"10024_CR31","doi-asserted-by":"crossref","unstructured":"Xu H, Qin J, Qin X, Guo C, Yang B (2022) Bioinformatics and in silico findings uncover bio-targets of calycosin against heart failure and diabetes mellitus. Front Endocrinol (Lausanne) 8(13):790619","DOI":"10.3389\/fendo.2022.790619"},{"issue":"14","key":"10024_CR32","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1001\/jama.2020.1906","volume":"323","author":"MC Petrie","year":"2020","unstructured":"Petrie MC, Verma S, Docherty KF, Inzucchi SE, Anand I, B\u011blohl\u00e1vek J et al (2020) Effect of dapagliflozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes. JAMA 323(14):1353\u20131368","journal-title":"JAMA"},{"issue":"2","key":"10024_CR33","first-page":"137","volume":"9","author":"MS Khan","year":"2021","unstructured":"Khan MS, Felker GM, Pi\u00f1a IL, Camacho A, Bapat D, Ibrahim NE et al (2021) Reverse cardiac remodeling following initiation of sacubitril\/valsartan in patients with heart failure with and without diabetes. Heart Fail 9(2):137\u2013145","journal-title":"Heart Fail"},{"issue":"1","key":"10024_CR34","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s12933-022-01545-1","volume":"21","author":"MO Wijkman","year":"2022","unstructured":"Wijkman MO, Claggett B, Vaduganathan M, Cunningham JW, R\u00f8rth R, Jackson A et al (2022) Effects of sacubitril\/valsartan on glycemia in patients with diabetes and heart failure: the PARAGON-HF and PARADIGM-HF trials. Cardiovasc Diabetol 21(1):110","journal-title":"Cardiovasc Diabetol"},{"issue":"19","key":"10024_CR35","doi-asserted-by":"crossref","first-page":"11934","DOI":"10.3390\/ijms231911934","volume":"23","author":"J Shou","year":"2022","unstructured":"Shou J, Huo Y (2022) PINK1 phosphorylates Drp1S616 to improve mitochondrial fission and inhibit the Progression of Hypertension-Induced HFpEF. Int J Mol Sci 23(19):11934","journal-title":"Int J Mol Sci"},{"issue":"19","key":"10024_CR36","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.3390\/cells11193032","volume":"11","author":"TK Bednarski","year":"2022","unstructured":"Bednarski TK, Duda MK, Dobrzyn P (2022) Alterations of lipid metabolism in the heart in spontaneously hypertensive rats precedes left ventricular hypertrophy and Cardiac Dysfunction. Cells 11(19):3032","journal-title":"Cells"},{"issue":"1","key":"10024_CR37","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/CRD.0000000000000173","volume":"26","author":"C Ashur","year":"2018","unstructured":"Ashur C, Frishman WH (2018) Cardiosphere-Derived cells and ischemic heart failure. Cardiol Rev 26(1):8\u201321","journal-title":"Cardiol Rev"},{"issue":"5","key":"10024_CR38","doi-asserted-by":"crossref","first-page":"H892","DOI":"10.1152\/ajpheart.00287.2022","volume":"323","author":"T Couto Gd, Mesquita","year":"2022","unstructured":"Couto Gd, Mesquita T, Wu X, Rajewski A, Huang F, Akhmerov A et al (2022) Cell therapy attenuates endothelial dysfunction in hypertensive rats with heart failure and preserved ejection fraction. Am J Physiol Heart Circ Physiol 323(5):H892\u2013H903","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"1","key":"10024_CR39","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1186\/s12864-022-08778-0","volume":"23","author":"R Zhang","year":"2022","unstructured":"Zhang R, Xu X, Chen X, Hao C, Ji Z, Zuo P et al (2022) Upregulation of key genes Eln and Tgfb3 were associated with the severity of cardiac hypertrophy. BMC Genomics 23(1):592","journal-title":"BMC Genomics"},{"key":"10024_CR40","doi-asserted-by":"crossref","unstructured":"Mithieux SM, Weiss AS (2005) Elastin. Advances in protein chemistry. 70:437\u2009\u2013\u200961","DOI":"10.1016\/S0065-3233(05)70013-9"},{"key":"10024_CR41","doi-asserted-by":"crossref","unstructured":"Ren H, Luo J-Q, Ouyang F, Cheng L, Chen X-P, Zhou H-H et al (2021) WNT3A rs752107(C\u2009>\u2009T) polymorphism is Associated with an increased risk of essential hypertension and related Cardiovascular diseases. Front Cardiovasc Med. 8","DOI":"10.3389\/fcvm.2021.675222"},{"key":"10024_CR42","doi-asserted-by":"crossref","unstructured":"MacDonnell S, Megna J, Ruan Q, Zhu O, Halasz G, Jasewicz D et al (2022) Activin A directly impairs human cardiomyocyte contractile function indicating a potential role in heart failure development. Front Cardiovasc Med. 9","DOI":"10.3389\/fcvm.2022.1038114"},{"issue":"6","key":"10024_CR43","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1177\/10742484211053109","volume":"26","author":"D Mondaca-Ruff","year":"2021","unstructured":"Mondaca-Ruff D, Araos P, Ya\u00f1ez CE, Novoa UF, Mora IG, Ocaranza MP et al (2021) Hydrochlorothiazide reduces cardiac hypertrophy, fibrosis and rho-kinase activation in DOCA-Salt Induced Hypertension. J Cardiovasc Pharmacol Therap 26(6):724\u2013735","journal-title":"J Cardiovasc Pharmacol Therap"},{"issue":"14","key":"10024_CR44","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1001\/jama.2022.4402","volume":"327","author":"NF Ruopp","year":"2022","unstructured":"Ruopp NF, Cockrill BA (2022) Diagnosis and treatment of pulmonary arterial hypertension: a review. JAMA 327(14):1379\u20131391","journal-title":"JAMA"},{"key":"10024_CR45","doi-asserted-by":"crossref","unstructured":"Morrell NW, Aldred MA, Chung WK, Elliott CG, Nichols WC, Soubrier F et al (2019) Genetics and genomics of pulmonary arterial hypertension. Eur Respir J. 53(1)","DOI":"10.1183\/13993003.01899-2018"},{"issue":"Suppl 2","key":"10024_CR46","doi-asserted-by":"crossref","first-page":"ii36","DOI":"10.1136\/heartjnl-2014-307238","volume":"102","author":"J Pattathu","year":"2016","unstructured":"Pattathu J, Gorenflo M, Hilgendorff A, Koskenvuo JW, Apitz C, Hansmann G et al (2016) Genetic testing and blood biomarkers in paediatric pulmonary hypertension. Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK. Heart 102(Suppl 2):ii36\u2013ii41","journal-title":"Heart"},{"key":"10024_CR47","doi-asserted-by":"crossref","unstructured":"Du M, Jiang H, Liu H, Zhao X, Zhou Y, Zhou F et al (2022) Single-cell RNA sequencing reveals that BMPR2 mutation regulates right ventricular function via ID genes. Eur Respir J. 60(1)","DOI":"10.1183\/13993003.00327-2021"},{"issue":"6","key":"10024_CR48","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1161\/HYPERTENSIONAHA.110.160515","volume":"56","author":"A-M Park","year":"2010","unstructured":"Park A-M, Wong C-M, Jelinkova L, Liu L, Nagase H, Suzuki YJ (2010) Pulmonary hypertension-induced GATA4 activation in the right ventricle. Hypertension 56(6):1145\u20131151","journal-title":"Hypertension"},{"issue":"5","key":"10024_CR49","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1165\/rcmb.2012-0429OC","volume":"48","author":"A Houssaini","year":"2013","unstructured":"Houssaini A, Abid S, Mouraret N, Wan F, Rideau D, Saker M et al (2013) Rapamycin reverses pulmonary artery smooth muscle cell proliferation in pulmonary hypertension. Am J Respir Cell Mol Biol 48(5):568\u2013577","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10024_CR50","doi-asserted-by":"crossref","first-page":"111395","DOI":"10.1016\/j.exger.2021.111395","volume":"151","author":"BD McNair","year":"2021","unstructured":"McNair BD, Schlatter JA, Cook RF, Yusifova M, Bruns DR (2021) Inhibition of mTOR by rapamycin does not improve hypoxic pulmonary hypertension-induced right heart failure in old mice. Exp Gerontol 151:111395","journal-title":"Exp Gerontol"},{"key":"10024_CR51","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1016\/j.biopha.2018.07.057","volume":"106","author":"Y Cao","year":"2018","unstructured":"Cao Y, Yang Y, Wang L, Li L, Zhang J, Gao X et al (2018) Analyses of long non-coding RNA and mRNA profiles in right ventricle myocardium of acute right heart failure in pulmonary arterial hypertension rats. Biomed Pharmacother 106:1108\u20131115","journal-title":"Biomed Pharmacother"},{"issue":"438","key":"10024_CR52","doi-asserted-by":"crossref","first-page":"eaao0303","DOI":"10.1126\/scitranslmed.aao0303","volume":"10","author":"E Legchenko","year":"2018","unstructured":"Legchenko E, Chouvarine P, Borchert P, Fernandez-Gonzalez A, Snay E, Meier M et al (2018) PPAR\u03b3 agonist pioglitazone reverses pulmonary hypertension and prevents right heart failure via fatty acid oxidation. Sci Transl Med 10(438):eaao0303","journal-title":"Sci Transl Med"},{"key":"10024_CR53","doi-asserted-by":"crossref","unstructured":"Frump AL, Albrecht M, Yakubov B, Breuils-Bonnet S, Nadeau V, Tremblay E et al (2021) 17\u03b2-Estradiol and estrogen receptor \u03b1 protect right ventricular function in pulmonary hypertension via BMPR2 and apelin. J Clin Investig. 131(6)","DOI":"10.1172\/JCI129433"},{"issue":"1","key":"10024_CR54","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1177\/039463201302600119","volume":"26","author":"C Falcone","year":"2013","unstructured":"Falcone C, Bozzini S, Matrone B, Colonna A, Falcone R, Calcagnino M et al (2013) RAGE gene polymorphism in heart failure patients with and without angiographic evidence of significant coronary atherosclerosis. Int J ImmunoPathol Pharmacol 26(1):199\u2013206","journal-title":"Int J ImmunoPathol Pharmacol"},{"key":"10024_CR55","doi-asserted-by":"crossref","unstructured":"Kravchun P, Kadykova O, Ryndina N, Krapivko S, Kozhyn M, Zolotaikina V (2020) Relationship between interleukin-6 gene polymorphism and heart failure in patients with coronary artery disease and obesity. Wiad Lek 73(8):1637\u20131640","DOI":"10.36740\/WLek202008109"},{"issue":"1","key":"10024_CR56","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/cpt.2153","volume":"110","author":"JL Katzmann","year":"2021","unstructured":"Katzmann JL, Mason AM, M\u00e4rz W, Kleber ME, Niessner A, Bl\u00fcher M et al (2021) Genetic variation in sodium-glucose cotransporter 2 and heart failure. Clin Pharmacol Ther 110(1):149\u2013158","journal-title":"Clin Pharmacol Ther"},{"key":"10024_CR57","doi-asserted-by":"crossref","unstructured":"Jin J, Zhu C, Wang J, Zhao X, Yang R (2022) The association between ACTB methylation in peripheral blood and coronary heart disease in a case-control study. Front Cardiovasc Med. 9","DOI":"10.3389\/fcvm.2022.972566"},{"issue":"1","key":"10024_CR58","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12933-020-01199-x","volume":"20","author":"SJ Nicholls","year":"2021","unstructured":"Nicholls SJ, Schwartz GG, Buhr KA, Ginsberg HN, Johansson JO, Kalantar-Zadeh K et al (2021) Apabetalone and hospitalization for heart failure in patients following an acute coronary syndrome: a prespecified analysis of the BETonMACE study. Cardiovasc Diabetol 20(1):1\u20139","journal-title":"Cardiovasc Diabetol"},{"key":"10024_CR59","doi-asserted-by":"crossref","unstructured":"Wang A, Zhao W, Yan K, Guo L, Gao F, Chen J et al (2022) Investigating the cardioprotective effects of Fuzheng Yangxin recipe based on network pharmacology and experimental evaluation. Front Pharmacol. 13","DOI":"10.3389\/fphar.2022.1004929"},{"issue":"9","key":"10024_CR60","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.3390\/ijms20092222","volume":"20","author":"JP Aboumsallem","year":"2019","unstructured":"Aboumsallem JP, Muthuramu I, Mishra M, De Geest B (2019) Cholesterol-lowering gene therapy prevents heart failure with preserved ejection fraction in obese type 2 diabetic mice. Int J Mol Sci 20(9):2222","journal-title":"Int J Mol Sci"},{"issue":"17","key":"10024_CR61","doi-asserted-by":"crossref","first-page":"6872","DOI":"10.18632\/aging.102218","volume":"11","author":"I Muthuramu","year":"2019","unstructured":"Muthuramu I, Mishra M, Aboumsallem JP, Postnov A, Gheysens O, De Geest B (2019) Cholesterol lowering attenuates pressure overload-induced heart failure in mice with mild hypercholesterolemia. Aging 11(17):6872","journal-title":"Aging"},{"key":"10024_CR62","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/164_2021_504","volume":"270","author":"F Kronenberg","year":"2022","unstructured":"Kronenberg F (2022) Lipoprotein (a). Handb Exp Pharmacol 270:201\u2013232","journal-title":"Handb Exp Pharmacol"},{"issue":"16","key":"10024_CR63","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1093\/eurheartj\/ehab804","volume":"43","author":"HD White","year":"2022","unstructured":"White HD, Schwartz GG, Szarek M, Bhatt DL, Bittner VA, Chiang C-E et al (2022) Alirocumab after acute coronary syndrome in patients with a history of heart failure. Eur Heart J 43(16):1554\u20131565","journal-title":"Eur Heart J"},{"issue":"5","key":"10024_CR64","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/MOL.0000000000000114","volume":"25","author":"TA Lagace","year":"2014","unstructured":"Lagace TA (2014) PCSK9 and LDLR degradation: regulatory mechanisms in circulation and in cells. Curr Opin Lipidol 25(5):387","journal-title":"Curr Opin Lipidol"},{"issue":"4","key":"10024_CR65","doi-asserted-by":"crossref","first-page":"247","DOI":"10.2217\/bmm-2020-0585","volume":"15","author":"E Bouwens","year":"2021","unstructured":"Bouwens E, Schuurman A-S, Akkerhuis KM, Manintveld OC, Caliskan K, van Ramshorst J et al (2021) Associations of serially measured PCSK9, LDLR and MPO with clinical outcomes in heart failure. Biomark Med 15(4):247\u2013255","journal-title":"Biomark Med"},{"issue":"17","key":"10024_CR66","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/j.jacc.2017.08.057","volume":"70","author":"A Bayes-Genis","year":"2017","unstructured":"Bayes-Genis A, N\u00fa\u00f1ez J, Zannad F, Ferreira JP, Anker SD, Cleland JG et al (2017) The PCSK9-LDL receptor axis and outcomes in heart failure: BIOSTAT-CHF subanalysis. J Am Coll Cardiol 70(17):2128\u20132136","journal-title":"J Am Coll Cardiol"},{"key":"10024_CR67","doi-asserted-by":"crossref","unstructured":"Laudette M, Lindbom M, Arif M, Cinato M, Ruiz M, Doran S et al (2023) Cardiomyocyte-specific PCSK9 deficiency compromises mitochondrial bioenergetics and heart function. Cardiovasc Res 119(7):1537\u20131552","DOI":"10.1093\/cvr\/cvad041"},{"issue":"32","key":"10024_CR68","doi-asserted-by":"crossref","first-page":"3078","DOI":"10.1093\/eurheartj\/ehab431","volume":"42","author":"L Da Dalt","year":"2021","unstructured":"Da Dalt L, Castiglioni L, Baragetti A, Audano M, Svecla M, Bonacina F et al (2021) PCSK9 deficiency rewires heart metabolism and drives heart failure with preserved ejection fraction. Eur Heart J 42(32):3078\u20133090","journal-title":"Eur Heart J"},{"issue":"2","key":"10024_CR69","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1001\/jamacardio.2022.4798","volume":"8","author":"LC Truds\u00f8","year":"2023","unstructured":"Truds\u00f8 LC, Ghouse J, Ahlberg G, Bundgaard H, Olesen MS (2023) Association of PCSK9 loss-of-function variants with risk of heart failure. JAMA Cardiol 8(2):159\u2013166","journal-title":"JAMA Cardiol"},{"key":"10024_CR70","doi-asserted-by":"crossref","unstructured":"Xiao J, Ji J, Yang X, Chen K, Chen L, Huang W (2022) Association of genetically-predicted lipid traits and lipid-modifying targets with the risk of heart failure. Eur J Prev Cardiol 30(4):358\u2013366","DOI":"10.1093\/eurjpc\/zwac290"},{"issue":"1","key":"10024_CR71","doi-asserted-by":"crossref","first-page":"H14","DOI":"10.1152\/ajpheart.00522.2022","volume":"324","author":"A Eirin","year":"2023","unstructured":"Eirin A, Chade AR (2023) Cardiac epigenetic changes in VEGF signaling genes associate with myocardial microvascular rarefaction in experimental chronic kidney disease. Am J Physiol Heart Circ Physiol 324(1):H14\u2013H25","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"4","key":"10024_CR72","doi-asserted-by":"crossref","first-page":"H659","DOI":"10.1152\/ajpheart.00333.2022","volume":"323","author":"AR Chade","year":"2022","unstructured":"Chade AR, Eirin A (2022) Cardiac micro-RNA and transcriptomic profile of a novel swine model of chronic kidney disease and left ventricular diastolic dysfunction. Am J Physiol Heart Circ Physiol 323(4):H659\u2013H69","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10024_CR73","first-page":"117793222110273","volume":"15","author":"MM Ahmed","year":"2021","unstructured":"Ahmed MM, Ishrat R, Tazyeen S, Alam A, Farooqui A, Ali R et al (2021) In silico integrative approach revealed key microRNAs and associated target genes in cardiorenal syndrome. Bioinform Biol Insights 15:11779322211027396","journal-title":"Bioinform Biol Insights"},{"key":"10024_CR74","unstructured":"Nicolas D, Kerndt CC, Reed M (2018) Sacubitril\/valsartan"},{"issue":"4","key":"10024_CR75","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1093\/ndt\/gfz058","volume":"35","author":"R Haynes","year":"2020","unstructured":"Haynes R, Zhu D, Judge PK, Herrington WG, Kalra PA, Baigent C (2020) Chronic kidney disease, heart failure and neprilysin inhibition. Nephrol Dialysis Transplantation 35(4):558\u2013564","journal-title":"Nephrol Dialysis Transplantation"},{"issue":"15","key":"10024_CR76","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1161\/CIRCULATIONAHA.118.034818","volume":"138","author":"R Haynes","year":"2018","unstructured":"Haynes R, Judge PK, Staplin N, Herrington WG, Storey BC, Bethel A et al (2018) Effects of sacubitril\/valsartan versus irbesartan in patients with chronic kidney disease: a randomized double-blind trial. Circulation 138(15):1505\u20131514","journal-title":"Circulation"},{"issue":"8","key":"10024_CR77","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1517\/13543784.2015.1059819","volume":"24","author":"LC Liu","year":"2015","unstructured":"Liu LC, Schutte E, Gansevoort RT, van der Meer P, Voors AA (2015) Finerenone: third-generation mineralocorticoid receptor antagonist for the treatment of heart failure and diabetic kidney disease. Expert Opin Investig Drugs 24(8):1123\u20131135","journal-title":"Expert Opin Investig Drugs"},{"issue":"11","key":"10024_CR78","first-page":"860","volume":"10","author":"G Filippatos","year":"2022","unstructured":"Filippatos G, Anker SD, Pitt B, Rossing P, Joseph A, Kolkhof P et al (2022) Finerenone and heart failure outcomes by kidney Function\/Albuminuria in chronic kidney disease and diabetes. JACC: Heart Fail 10(11):860\u2013870","journal-title":"JACC: Heart Fail"},{"issue":"27","key":"10024_CR79","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1093\/eurheartj\/ehw132","volume":"37","author":"G Filippatos","year":"2016","unstructured":"Filippatos G, Anker SD, B\u00f6hm M, Gheorghiade M, K\u00f8ber L, Krum H et al (2016) A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and\/or chronic kidney disease. Eur Heart J 37(27):2105\u20132114","journal-title":"Eur Heart J"},{"issue":"5","key":"10024_CR80","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMoa1707855","volume":"378","author":"NF Marrouche","year":"2018","unstructured":"Marrouche NF, Brachmann J, Andresen D, Siebels J, Boersma L, Jordaens L et al (2018) Catheter ablation for atrial fibrillation with heart failure. N Engl J Med 378(5):417\u2013427","journal-title":"N Engl J Med"},{"issue":"2","key":"10024_CR81","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/cpt.717","volume":"102","author":"R Arora","year":"2017","unstructured":"Arora R (2017) Gene therapy for atrial fibrillation in heart failure. Clin Pharmacol Ther 102(2):200\u2013202","journal-title":"Clin Pharmacol Ther"},{"issue":"12","key":"10024_CR82","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/j.hrthm.2022.08.019","volume":"19","author":"S Zeemering","year":"2022","unstructured":"Zeemering S, Isaacs A, Winters J, Maesen B, Bidar E, Dimopoulou C et al (2022) Atrial fibrillation in the presence and absence of heart failure enhances expression of genes involved in cardiomyocyte structure, conduction properties, fibrosis, inflammation, and endothelial dysfunction. Heart Rhythm 19(12):2115\u20132124","journal-title":"Heart Rhythm"},{"issue":"10","key":"10024_CR83","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.3390\/medicina58101319","volume":"58","author":"Y Zhuang","year":"2022","unstructured":"Zhuang Y, Qiao Z, Bi X, Han D, Jiang Q, Zhang Y et al (2022) Screening and Bioinformatics Analysis of Crucial Gene of Heart failure and Atrial Fibrillation based on GEO Database. Medicina 58(10):1319","journal-title":"Medicina"},{"issue":"3","key":"10024_CR84","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.amjcard.2008.03.063","volume":"102","author":"O Amir","year":"2008","unstructured":"Amir O, Amir RE, Paz H, Mor R, Sagiv M, Lewis BS (2008) Aldosterone synthase gene polymorphism as a determinant of atrial fibrillation in patients with heart failure. Am J Cardiol 102(3):326\u2013329","journal-title":"Am J Cardiol"},{"issue":"5","key":"10024_CR85","doi-asserted-by":"crossref","first-page":"H1814","DOI":"10.1152\/ajpheart.00771.2010","volume":"300","author":"K Kitamura","year":"2011","unstructured":"Kitamura K, Shibata R, Tsuji Y, Shimano M, Inden Y, Murohara T (2011) Eicosapentaenoic acid prevents atrial fibrillation associated with heart failure in a rabbit model. Am J Physiol Heart Circ Physiol 300(5):H1814\u2013H21","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10024_CR86","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s00392-010-0248-1","volume":"100","author":"M Behnes","year":"2011","unstructured":"Behnes M, Hoffmann U, Lang S, Weiss C, Ahmad-Nejad P, Neumaier M et al (2011) Transforming growth factor beta 1 (TGF-beta 1) in atrial fibrillation and acute congestive heart failure. Clin Res Cardiol 100:335\u2013342","journal-title":"Clin Res Cardiol"},{"issue":"4","key":"10024_CR87","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.3390\/jcm12041537","volume":"12","author":"S Ma","year":"2023","unstructured":"Ma S, Yan F, Hou Y (2023) Intermedin 1\u201353 ameliorates Atrial Fibrosis and reduces inducibility of Atrial Fibrillation via TGF-\u03b21\/pSmad3 and Nox4 pathway in a rat model of heart failure. J Clin Med 12(4):1537","journal-title":"J Clin Med"},{"issue":"11","key":"10024_CR88","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/s41569-020-0394-8","volume":"17","author":"H Dridi","year":"2020","unstructured":"Dridi H, Kushnir A, Zalk R, Yuan Q, Melville Z, Marks AR (2020) Intracellular calcium leak in heart failure and atrial fibrillation: a unifying mechanism and therapeutic target. Nat Reviews Cardiol 17(11):732\u2013747","journal-title":"Nat Reviews Cardiol"},{"issue":"2","key":"10024_CR89","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.hroo.2020.03.004","volume":"1","author":"C Nofi","year":"2020","unstructured":"Nofi C, Zhang K, Tang Y-D, Li Y, Migirov A, Ojamaa K et al (2020) Chronic dantrolene treatment attenuates cardiac dysfunction and reduces atrial fibrillation inducibility in a rat myocardial infarction heart failure model. Heart Rhythm O2 1(2):126\u2013135","journal-title":"Heart Rhythm O2"},{"issue":"7","key":"10024_CR90","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.hrthm.2019.01.013","volume":"16","author":"Z Liu","year":"2019","unstructured":"Liu Z, Finet JE, Wolfram JA, Anderson ME, Ai X, Donahue JK (2019) Calcium\/calmodulin-dependent protein kinase II causes atrial structural remodeling associated with atrial fibrillation and heart failure. Heart Rhythm 16(7):1080\u20131088","journal-title":"Heart Rhythm"},{"key":"10024_CR91","doi-asserted-by":"crossref","unstructured":"Femminella GD, Pagano G, Liccardo D, Cannavo A (2021) Molecular mechanisms involved in heart failure, Parkinson\u2019s, and Alzheimer\u2019s diseases. Frontiers Media SA, p 754987","DOI":"10.3389\/fmolb.2021.754987"},{"issue":"3","key":"10024_CR92","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3892\/br.2023.1607","volume":"18","author":"L Grosu","year":"2023","unstructured":"Grosu L, Grosu AI, Crisan D, Zlibut A, Perju-Dumbrava L (2023) Parkinson\u2019s disease and cardiovascular involvement: edifying insights. Biomedical Rep 18(3):1\u20138","journal-title":"Biomedical Rep"},{"issue":"3","key":"10024_CR93","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1517\/14740338.2014.888057","volume":"13","author":"S Perez-Lloret","year":"2014","unstructured":"Perez-Lloret S, Rey MV, Crispo J, Krewski D, Lapeyre-Mestre M, Montastruc J-L et al (2014) Risk of heart failure following treatment with dopamine agonists in Parkinson\u2019s disease patients. Exp Opin Drug Saf 13(3):351\u2013360","journal-title":"Exp Opin Drug Saf"},{"key":"10024_CR94","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1007\/s40263-015-0293-4","volume":"29","author":"T Tran","year":"2015","unstructured":"Tran T, Brophy JM, Suissa S, Renoux C (2015) Risks of cardiac valve regurgitation and heart failure associated with ergot-and non-ergot-derived dopamine agonist use in patients with Parkinson\u2019s disease: a systematic review of observational studies. CNS Drugs 29:985\u2013998","journal-title":"CNS Drugs"},{"issue":"2","key":"10024_CR95","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1097\/MS9.0000000000001642","volume":"86","author":"LVS Kutikuppala","year":"2024","unstructured":"Kutikuppala LVS, Sharma S, Chavan M, Rangari G, Misra AK, Innamuri SR et al (2024) Bromocriptine: does this drug of Parkinson\u2019s disease have a role in managing cardiovascular diseases? Annals Med Surg 86(2):926\u2013929","journal-title":"Annals Med Surg"},{"issue":"2","key":"10024_CR96","doi-asserted-by":"crossref","first-page":"e16110","DOI":"10.1111\/ene.16110","volume":"31","author":"V Kincl","year":"2024","unstructured":"Kincl V, Panovsk\u00fd R, Bo\u010dkov\u00e1 M, Rektor I, Mojica-Pisciotti ML, M\u00e1chal J (2024) Parkinson\u00b4 s disease cardiovascular symptoms: a new complex functional and structural insight. Eur J Neurol 31(2):e16110","journal-title":"Eur J Neurol"},{"key":"10024_CR97","doi-asserted-by":"crossref","unstructured":"Ukenenye E, Oshiba T, Okoronkwo E, Obomanu E, Asaolu G, Urhi A et al (2023) Quivering hand and heart: Parkinson\u2019s disease is not associated with increased in-hospital mortality in atrial fibrillation hospitalizations: A nationwide analysis. Heliyon. 9(4)","DOI":"10.1016\/j.heliyon.2023.e14725"},{"issue":"1","key":"10024_CR98","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/abbs\/gmz115","volume":"52","author":"M Yang","year":"2020","unstructured":"Yang M, Li C, Zhang Y, Ren J (2020) Interrelationship between Alzheimer\u2019s disease and cardiac dysfunction: the brain\u2013heart continuum? Acta Biochim Biophys Sin 52(1):1\u20138","journal-title":"Acta Biochim Biophys Sin"},{"key":"10024_CR99","doi-asserted-by":"crossref","unstructured":"Peikert A, Cunningham JW (2023) Amyloid-\u03b2 and the risk of Heart failure: cause or only Association? American College of Cardiology Foundation Washington DC, pp 103\u2013105","DOI":"10.1016\/j.jchf.2022.09.010"},{"issue":"5","key":"10024_CR100","doi-asserted-by":"crossref","first-page":"e18492","DOI":"10.1097\/MD.0000000000018492","volume":"99","author":"J Li","year":"2020","unstructured":"Li J, Wu Y, Zhang D, Nie J (2020) Associations between heart failure and risk of dementia: a PRISMA-compliant meta-analysis. Medicine 99(5):e18492","journal-title":"Medicine"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-024-10024-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-024-10024-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-024-10024-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T04:43:00Z","timestamp":1738730580000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-024-10024-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,26]]},"references-count":100,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["10024"],"URL":"https:\/\/doi.org\/10.1007\/s11033-024-10024-7","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,26]]},"assertion":[{"value":"19 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1092"}}